Deepak Tiwari, PhD, Joins Particle Sciences as Director of Formulation and Process Development

BETHLEHEM, Pa., Jan. 8, 2013 /PRNewswire/ -- Particle Sciences, Inc. today announced the appointment of Deepak Tiwari, PhD to the position of Director, Formulation and Process Development. Dr. Tiwari, who holds a PhD in Pharmaceutical Sciences from St. John's University, joins Particle Sciences following more than 18 years' experience in pharmaceutical development roles. Most recently, he served as Director, Pharmaceutical Development at Agennix Inc. Prior to that, Dr. Tiwari held senior positions at Baxter and Bayer. His areas of expertise include formulation development, clinical trial materials manufacturing, and commercial scale manufacturing of drug products. He has been integral to over 20 regulatory submissions worldwide and 7 marketed drug products. Dr. Mark Mitchnick, Particle Sciences' CEO, notes that, "Deepak brings a wealth of experience to the Particle Sciences team. His deep later stage development experience nicely compliments Particle Sciences business. Additionally, Deepak has been involved in a wide variety of dosage forms including sterile products for both small and large biologic molecules, and this too parallels Particle Sciences' client base."

Particle Sciences is an integrated provider of drug formulation and development services. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano technologydrug/device combination products, solid solutions and others. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered inBethlehem, Pennsylvania., email [email protected] or contact us at (610) 861- 4701 for information.

Contact: Maureen Mattera
[email protected]

SOURCE Particle Sciences, Inc.

Suggested Articles

Can an unexpected Sarepta win be good news for Biogen?

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.